CP
LBRX

Caligan Partners’s LB Pharmaceuticals LBRX Stock Holding History

Caligan Partners’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.6M Buy
+1,438,070
New +$33.2M 2.3% 13

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Caligan Partners's LBRX Position: Q1 2026 in Review

Caligan Partners opened a new position in LB Pharmaceuticals (LBRX) in Q1 2026: 1,438,070 shares worth $34.6M. The stake represents 2.3% of the portfolio and ranks #13 among its holdings.

77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Caligan Partners held 1,438,070 shares of LB Pharmaceuticals worth $34.6M as of Q1 2026.
  • LB Pharmaceuticals was a new Caligan Partners position in Q1 2026.
  • LB Pharmaceuticals made up 2.3% of Caligan Partners's portfolio in Q1 2026, its #13 holding.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.